Gland Pharma reports 50% profit jump, Cenexi turnaround

Gland Pharma reported a 50% jump in profit to ₹2,155 million for Q1 FY26, with revenue rising 7% to ₹15,056 million.

The company's troubled French unit Cenexi achieved EBITDA breakeven, contributing to a 20% increase in gross margin. Cenexi's revenue grew 19% in euro terms.

Gland Pharma launched 12 new molecules including Liraglutide and secured nine regulatory approvals during the quarter.